Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ciphergen Biosystems(CIPH): -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (397)	1/13/2006 2:23:31 PM
From: tuck	Respond to of 510

[Biomarker discovery for ovarian cancer using SELDI-TOF-MS] >>Gynecol Oncol. 2006 Jan 3; [Epub ahead of print] Biomarker discovery for ovarian cancer using SELDI-TOF-MS. Zhang H, Kong B, Qu X, Jia L, Deng B, Yang Q. Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Ji'nan 250012, Shandong Province, P.R. China. OBJECTIVES.: The purpose of this study is to discover potential biomarkers for the detection and monitoring of adjuvant chemotherapy for ovarian cancer. METHODS.: Serum samples from ovarian cancers and non-cancer controls were analyzed using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS). To discover the possible diagnostic biomarker for ovarian cancer, a preliminary training set of spectra derived from 31 primary ovarian cancer patients, 16 patients with benign ovarian diseases, and 25 healthy women was used to develop a proteomic model that discriminated cancer from non-cancer effectively. A blind test set, including 43 new cases, was used to validate the sensitivity and specificity of this multivariate model. To explore treatment-induced serum protein change, the protein profiles generated from 16 postoperative patients before chemotherapy are compared with those obtained after chemotherapy. RESULTS.: A Four-peak model was established in the training set that discriminated cancer from non-cancer with sensitivity of 90.8% and specificity of 93.5%. A sensitivity of 87.0% and a specificity of 95.0% for the blind test were obtained, compared with 60.7%, 55% for CA125 for the same samples. These 4 markers performed significantly better than the current standard marker, CA125 (P < 0.05). One protein peak (mass/charge ratio [m/z], 4475) was identified in 12 of 16 (75%) postoperative patients after chemotherapy, but was absent before chemotherapy. CONCLUSION.: The proteins represented by these peaks are candidate biomarkers for ovarian cancer diagnosis and/or monitoring treatment response.<< Cheers, Tuck

To: tuck who wrote (397)	4/7/2007 12:25:42 PM
From: tuck	Respond to of 510

[SELDI-TOF MS versus prostate specific antigen analysis of prospective plasma samples in a nested case-control study of prostate cancer.] >>Int J Cancer. 2007 Apr 4; [Epub ahead of print] SELDI-TOF MS versus prostate specific antigen analysis of prospective plasma samples in a nested case-control study of prostate cancer. Skytt A, Thysell E, Stattin P, Stenman UH, Antti H, Wikstrom P. Department of Medical Biosciences, Pathology, Umea University, Umea, Sweden. There is an urgent need for better biomarkers for detection of clinically significant prostate cancer (PCa). Recent studies suggest that surface enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) analysis of serum may provide diagnostic information. The aim of this study was to investigate if PCa cases could be identified by applying predefined SELDI-TOF analysis conditions on prospectively, uniformly collected plasma samples from PCa cases and matched controls. Prospective samples from 387 incident PCa cases and an equal number of controls, matched for age and time for recruitment, were analyzed by SELDI-TOF MS (IMAC30/Cu chip) and multivariate classification analysis. Prospective prostate specific antigen levels were subjected to ROC curve analysis giving an AUC of 0.87 for the total cohort with a median lag time between blood sampling and diagnosis of 6.1 years. No markers were found by SELDI-TOF MS that significantly discriminated between cases and controls in the total cohort or in subanalysis of cases with less than 2 years between blood donation and diagnosis (n = 42). Cases with aggressive disease at the time of diagnosis who gave blood less than 4 years prior to diagnosis (n = 23) could however be separated from their controls (sensitivity 70%, specificity 83%) by a model based on SELDI-TOF MS and OPLS-DA data analysis. We were thus not able to confirm previous results with SELDI-TOF MS identifying men with PCa from healthy individuals, but we report an optimal experimental set-up for verification of markers for early detection of cancer in prospectively collected samples.<< This seems well controlled and done, but the parameters seem rather ambitious. That they got signal in men with aggressive disease is somewhat promising (the sensitivity, specificity, and -- by inference -- predictive value aren't looking too good here). But they couldn't confirm someone's studies. Guess we'd have to buy the article to know which ones they are referring to. Cheers, Tuck